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Abstract
Purpose: The study aims to assess the feasibility of tomotherapy-based image-guided (IGRT) radiotherapy for locally
advanced oropharyngeal cancer. A retrospective review of 33 patients undergoing concurrent chemoradiation for locally
advanced oropharyngeal cancers was conducted. Radiotherapy planning, treatment toxicity and loco-regional control were
assessed.
Results: At a median follow-up of 32 months (6–47 months), no patient developed loco-regional recurrence. Two patients
(6%) developed distant metastases. Grade 3–4 acute toxicity was respectively 72% and 25% for mucositis and
gastrointestinal toxicity. Two patients (6%) had long-term dependence on tube feedings. Dose-volume histogram
demonstrated excellent target volume coverage and low radiation dose to the organs at risk for complications.
Conclusions and clinical relevance: IGRT provides excellent loco-regional control but acute toxicity remains significant and
needs to be addressed in future prospective trials. The feasibility of Tomotherapy to decrease radiation dose to the normal
tissues merits further investigations.
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Introduction
The prevalence of oropharyngeal cancer is steadily rising in the
United States despite a reduction of other head and neck cancers
[1]. The increase in oropharyngeal cancers is mainly observed in
young patients and related to human papilloma virus (HPV) 16
which may reach epidemic proportion [2]. Most patients with
oropharyngeal malignancyare frequently diagnosed at advanced
stages because the submucosal spread of the tumor making it
difficult to detect clinically despite patient’s symptoms [3]. Locally
advanced oropharyngeal cancers can be treated with either
surgery followed by postoperative radiation or concurrent
chemoradiation with similar survival [4]. Resection of the tongue
base or soft palate is frequently associated with significant
morbidity because of the crucial role of these organs in speech
and deglutition [5,6]. In addition, neck dissection, often bilateral,
may induce severe pain because of nerve damage which may
decrease patient quality of life [7]. Thus, concurrent chemoradia-
tion is frequently selected over surgery for patients with locally
advanced oropharyngeal cancers because of anatomic organ
preservation [8]. However, chemoradiation is associated with
significant toxicity, mainly grade 3–4 mucositis and hematologic
toxicity, and long-term dysphagia because of damage to the
pharyngeal muscles [9,10]. New radiotherapy technique such as
intensity-modulated radiotherapy (IMRT) has been introduced to
decrease treatment toxicity in oropharyngeal cancers with
promising preliminary results despite a short follow-up [11].
Image-guided radiotherapy (IGRT) is a new technique of IMRT
delivery which combines the sharper dose fall off of IMRT and
precise target irradiation [12]. The feasibility of IGRT has not
been fully investigated in locally advanced oropharyngeal cancer
and prompt us to conduct this retrospective study.
Materials and Methods
The medical records of 33 patients undergoing radiotherapy for
locally advanced oropharyngeal cancers at the University of
Arizona Radiation Oncology department were retrospectively
reviewed following institutional review board (IRB) approval from
the University of Arizona. The University of Arizona IRB waived
the requirement for patient consent because of the retrospective
nature of the study limited to charts review. Patient information
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was de-identified to protect patient confidentiality. All patients
were treated with the whole field IGRT technique on the helical
Tomotherapy unit from December 2008 to February 2011. Prior
to treatment, each patient was simulated in the supine position
with a head and neck aquaplast mask for treatment immobiliza-
tion. A computed tomography (CT) scan with and without
intravenous (IV) contrast for treatment planning was performed in
the treatment position. The head and neck areas from the vertex
to the mid thorax were scanned with a slice thickness of 3 mm CT
scan with IV contrast was employed to outline the tumor and
grossly enlarged cervical lymph node for target volume delinea-
tion. Radiotherapy planning was performed on the CT scan
without contrast to avoid possible interference of contrast density
on radiotherapy isodose distributions. Diagnostic positron emis-
sion tomography (PET)-CT scan planning for tumor imaging was
also incorporated with CT planning when available for tumor
imaging. A 0.5 cm bolus material was placed on any area of the
skin involved by the tumor and on any palpable cervical lymph
nodes. Normal organs at risk for complication were outlined for
treatment planning (spinal cord, brain stem, bilateral cochlea,
mandible, parotid glands, bilateral eyes, and oral cavity).
For patients with definitive chemoradiation, the tumor and
grossly enlarged lymph nodes (CTV1) on CT scan with a margin
(PTV1) were treated to 70 Gy in 35 fractions (2 Gy/fraction). The
margins were 5 mm to 1 cm all around CTV1 depending on
anatomic location. The areas at high risk-PTV2 (at least 1 cm
around gross tumor and pathologic cervical lymph nodes) and low
risk -PTV3 (subclinical regional lymph nodes with 5 mm margins)
for tumor spread were treated respectively to 63 Gy and 56 Gy in
35 fractions, respectively. Patients undergoing postoperative
chemoradiation were treated to 66 Gy, 59.4 Gy, and 54 Gy in
33 fractions to PTV1, PTV2, and PTV3 respectively. Indications
for postoperative chemoradiation were positive margins and/or
extra-capsular lymph nodes invasion. Minimal target coverage was
95% of the prescribed dose for all targets with at least 99% of the
prescribed dose delivered to gross tumor and involved cervical
lymph nodes. The lymph nodes in the ipsilateral neck including
the retropharyngeal lymph nodes were treated to the base of skull
if there was any cervical lymph node enlargement (or PET-positive
lymph nodes). Contralateral uninvolved lymph nodes were treated
prophylactically with the C1 vertebrae as the superior border of
the radiation field. In case of bilateral cervical lymph node
involvement, both sides of the neck were irradiated including the
base of skull to avoid any marginal miss. Mean dose to the parotid
was kept below 2600 cGy if there was no ipsilateral cervical lymph
node enlargement. Dose constraints for other normal organs at
risk (OAR) for complications were: spinal cord (45 Gy), brain stem
(50 Gy), optic chiasm (45 Gy), mandible (70 Gy to less than 30%
of the mandible).
Concurrent chemoradiation was recommended for all patients.
The type of chemotherapy regimen was left at the discretion of the
medical oncologists depending on patient functional status and co-
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Treatment Radiotherapy alone 1
Postoperative chemoradiation 5
Chemoradiation 27
Smoking history .50-pack year history 31
Follow-up (months) Median 28
Range 6–43
doi:10.1371/journal.pone.0060268.t001
Table 2. Dose distribution to target volume and to critical
organs at risk for complications following image-guided







Spinal cord Maximum 36.7 Gy
Range 28.9–42 Gy
Brain stem Maximum 44.5 Gy
Range 35.7–50.2 Gy
Right parotid Mean 39 Gy
Range 18.4–65.4 Gy
Left parotid Mean 37.6 Gy
Range 19.6–63.8 Gy
Larynx Mean 24.5 Gy
Range 17.3–45.5 Gy
Right cochlea Mean 6.9 Gy
Range 3.6–14.3 Gy
Left cochlea Mean 8.7 Gy
Range 4–28.4 Gy




PTV1: target volume receiving 66 to 70 Gy; PTV2: target volume receiving 59.6
to 63 Gy; PTV3: target volume receiving 54 to 56 Gy; Gy: gray.
doi:10.1371/journal.pone.0060268.t002
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morbidities. Prophylactic percutaneous gastrostomy tubes feedings
placement was recommended for all patients prior to radiotherapy
because of the expected weight loss secondary to chemoradiation-
induced mucositis. Weekly complete blood count (CBC) and blood
chemistry to assess renal function were performed during
chemoradiation. Treatment breaks and weight loss were recorded
during chemoradiation. Acute and long-term toxicities were
graded according to Radiotherapy Oncology Group (RTOG)
group severity scale (http://ctep.cancer.gov).
All patients had a follow-up visit one month and regularly three
months following treatment. Clinical examination and direct
endoscopic exam were performed at each follow-up to detect
recurrent disease. A PET scan or PET-CT scan were performed
four months, ten months and yearly after treatment if there was no
evidence of disease. PET positive areas were biopsied to detect
recurrence and surgery and/or chemotherapy were carried out for
salvage if the biopsy demonstrated disease recurrence. Patient
ability to resume normal oral feeding and dependency on tube
feedings was also evaluated at each visit.
Survival data was analyzed using Kaplan-Meier estimation.
Results
We identified 33 patients with invasive squamous cell carcinoma
of the oropharynx treated at the University of Arizona Radiation
Oncology department from 2007 to 2011.
Median age at diagnosis was 61 years-old (range: 39-83 years-
old). There were 31 males and 2 female. There was 7 stage III, 19
stage IVA, 5 stage IVB and two stage IVC. Treatment consisted
of: radiotherapy alone (1), postoperative chemoradiation (5), and
definitive concurrent chemoradiation (27). The patient who had
radiotherapy alone did not have chemotherapy because of
significant co-morbidity with recurrent pneumonia prior to
treatment. Except for two patients, all patients had a smoking
history. Three patients had HPV 16 testing because of their young
age and absence of smoking history. Two of these three patients
were HPV 16 positive. Radiotherapy technique consisted of WF
IGRT on the helical Tomotherapy unit. Table 1 summarizes
patient characteristics. Table 2 summarizes radiation dose
distributions among various OAR and to PTV1-3.
Chemotherapy consisted of cisplatin (P) 30 mg/m2 intrave-
nously (IV) weekly (21) and cisplatin 100 mg IV on day 1, 22, and
43 of radiotherapy (7). One patient had carboplatin IV weekly
with an area under the curve (AUC) of 1.5 because poor kidney
function. Three patient had induction chemotherapy with taxotere
(T) 75 mg/m2 IV, cisplatin 100 mg/m2 IV followed by 5-
fluorouracil (F) 1000 mg/m2 for four days, repeated every three
weeks for three cycles followed four weeks later by carboplatin IV
weekly with an area under the curve of 1.5 during radiotherapy.
One patient had cetuximab IV 400 mg/m2 followed by 250 mg/
m 2 weekly during radiotherapy because of concern that he may
not tolerate conventional chemotherapy.
At a median follow-up of 32 months (6–47 months), no patient
developed loco-regional recurrence. The two stages IVc patients
had lung metastases on diagnosis. They had induction chemo-
therapy followed by concurrent chemoradiation. The lung
metastases initially responded to induction chemotherapy but
recurred four to six months respectively after chemoradiation
requiring adjuvant chemotherapy and stereotactic body radio-
therapy. One patient developed hematuria after chemoradiation.
He was diagnosed to have locally advanced bladder cancer and
died from the bladder cancer. The 3-year survival is estimated to
be 92% for the whole group.
Twenty-four patients (72%) developed grade 3-4 toxicity
mucositis. Six patients (25%) had grade 3–4 nausea and vomiting
requiring IV fluid for hydration.
The patient who had recurrent pneumonia prior to radiother-
apy continued to have pneumonia during treatment and required
multiple hospital admissions.
Two patients did not complete radiotherapy. One patient
decided against medical advice to discontinue treatment at 48 Gy
because of grade 4 mucositis. One patient was involved in a car
accident and treatment was stopped at 68 Gy. Eighteen patients
(54%) had treatment breaks ranging from three to 28 days
(median: 3 days) because of grade 3–4 toxicity. Median weight loss
was 16 pounds (0–40 pounds).
Chemotherapy was not administered according to the protocol
in six patients (18%).
One patient did not receive chemotherapy because of recurrent
pneumonia prior to treatment and the concern for chemotherapy-
induced immunosuppression. The patient who had induction TPF
had 25% TPF dose reduction after the first cycle of chemotherapy
because of neutropenia. Among patients who had weekly cisplatin
30 mg/m2, one patient developed acute tubular necrosis after the
first week of chemotherapy which required its replacement with
carboplatin, another patient had cisplatin on hold during week 5
because of severe vomiting. The patient who had weekly
carboplatin did not receive carboplatin after week 5 because of
severe weight loss and PEG tube malfunction.
For the whole group of 33 patients, two (6%) had prolonged
tube feedings at 21 months and 29 months respectively because of
severe dysphagia and dysgueusia. They were able to discontinue
tube feedings afterward. One patient (3%) had soft tissue mucosal
ulceration which resolved with antibiotics and oral hygiene.
Discussion
To our knowledge, this is the first study looking at the feasibility
of chemoradiation for locally advanced oropharyngeal cancer with
tomotherapy-based IGRT and PET imaging. Even though the
patient number is small with a relatively short follow-up, all
patients achieved clinical and PET proven loco-regional control.
We include two patients who had lung metastases at diagnosis
because they were in remission following induction chemotherapy
and required radiotherapy for local control. Even though the lung
metastases recurred after chemoradiation, they did not have loco-
regional failure even though they both had large size primaries
and neck nodes (T4,N3). Even though we lacked information on
HPV 16 status in most patients, the majority of the patients had a
history of heavy smoking which conferred a poor prognosis.
Tomotherapy is able to deliver a high radiation dose with rapid fall
off. In addition, pre-treatment megavolt (MV) CT performed
before treatment and re-positioning to compensate for body
motion and tumor shrinkage decreased the risk of marginal miss
[13–17].
As we reported previously, the study mean laryngeal and
cochlea dose remained consistently low [16,18]. Low dose to the
larynx may reduce the risk of laryngeal edema and preserve voice
quality. Decreased cochlea dose may decrease the risk of hearing
loss and potentially improve patient quality of life because of the
proven ototoxicity of cisplatin-based chemotherapy. The mean
parotid dose was high because most of the patients presented with
cervical lymph node metastases at diagnosis. It is our policy not to
spare the ipsilateral parotid gland in case of neck node
involvement because of the risk recurrence in the peri-parotid
area [19]. As a result, loco-regional control was excellent despite
locally advanced disease. For instance, Figure 1 illustrated a
Tomotherapy and Oropharyngeal Cancer
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patient with a T4N3M1 (IVc) base of tongue carcinoma who
presented with lung metastases at diagnosis. Following induction
chemotherapy with TPF, the patient underwent concurrent
chemoradiation with complete resolution of the gross tumor and
cervical lymph nodes on follow-up PET-CT. The lung metastases
were treated with adjuvant chemotherapy and stereotactic body
irradiation. The patient is currently on remission two years after
treatment with no long-term complications because of the low
dose of radiation to the normal tissues. Even though the study
follow-up is relatively short, PET-CT following treatment allows us
to detect disease recurrence or second primaries effectively [20–
23]. Indeed, the patient who had biopsy-proven bladder cancer
was diagnosed on PET-CT. PET-CT may also have predictive
prognostic value. In a study of 80 head and neck cancer patients
who underwent radiotherapy and were monitored with PET-CT,
the patients who had a negative PET-CT within six months of
treatment completion had a 2-year disease-free survival of 93%
[20]. The high accuracy rate of PET-CT in predicting survival
benefit for patients who were disease-free by PET criterias
following radiotherapy or chemoradiation for head and neck
cancer was also corroborated in other studies [21–23]. Thus, we
feel confident that the excellent loco-regional control observed in
our study may be maintained with a longer follow-up.
We observe a high rate of grade 3–4 mucositis and gastroin-
testinal toxicity during treatment. The combination of chemo-
therapy and radiation for locally advanced oropharyngeal cancer
is frequently associated with significant acute toxicity because of
the large volume of normal tissues irradiated even with IMRT
Figure 1. Illustration of the effectiveness of Tomotherapy to deliver high radiation dose to the gross tumor and cervical lymph
nodes while sparing adjacent normal structures. The patient had locally advanced base of the tongue cancer (T4) associated with massive
cervical metastases (N3) and lung metastases at diagnosis. Following induction chemotherapy which resulted in resolution of the lung metastases, he
had concurrent chemoradiation for local control and achieved a complete response of the gross tumor and lymph nodes on post-treatment PET-CT.
The lung metastases recurred after treatment and were treated with adjuvant chemotherapy and consolidation stereotactic body radiotherapy. The
patient is currently on remission two years after the treatment with no long-term complications except for xerostomia because of low radiation dose
to the normal organs. The parotid glands could not be spared because of the close proximity to the gross lymph nodes and areas at high risk for
disease.Red line: gross tumor and cervical lymph nodes treated to 70 Gy; green line: area at high risk for disease treated to 63 Gy; pink line:
mandibular dose (mean: 56 Gy), gray line: pharyngeal muscles dose (mean: 33.6 Gy); gray-blue line: laryngeal dose (mean: 22.5 Gy); navy blue line:
spinal cord dose (max: 39.4 Gy); light blue line: right cochlea dose: (mean: 4.5 Gy); light brown line: left cochlea dose: (mean: 5.3 Gy).
doi:10.1371/journal.pone.0060268.g001
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[11,24]. However, the acute toxicity frequently resolved by four to
six weeks after chemoradiation. We have a special team of
dietitians, speech pathologists, and home health nurses who
monitored patients closely during and after treatment because of
the significant weight loss secondary to mucositis. Only two
patients (6%) became dependent on long-term tube feedings
because chronic dysphagia and dysgueusia. They eventually
recovered andhad removal of the feedings tubes. If we look at
the long-term toxicity of patients with locally advanced oropha-
ryngeal cancer treated with concurrent chemotherapy and
conventional radiotherapy, up to 37% of the patients had
prolonged tube feedings after treatment because of severe
dysphagia or aspiration [9]. Long-term dependence on feeding
tubes was also observed in 14% of the patients treated with IMRT
and chemotherapy for oropharyngeal cancer [11]. Even with a
special IMRT technique designed to reduce irradiation to the
larynx and pharyngeal muscles which are critical structures for
swallow, four out of 76 patients (5%) still experienced significant
dysphagia one year following chemoradiation for oropharyngeal
cancer [25].
Thus, our treatment complications profile compares favorably
with other studies on oropharyngeal cancers and may improve
further in the future as we acquire more experience with this new
technique of radiotherapy. We also consider the administration of
amifostine, a radiation protector, during chemoradiation for
oropharyngeal cancers in the future to reduce the severity of
mucositis and long-term dysphagia [26,27].
The limitations of the present study include the retrospective
nature of the study, the small number of patients, the lack of HPV
16 information on most patients, and the relatively short follow-
up. We do not have a matched cohort of oropharyngeal cancer
patients treated with the conventional radiotherapy technique
because these patients did not have a dose-volume histogram for
comparison. However, our study demonstrates the feasibility of
tomotherapy treatment for local control in patients with locally
advanced oropharyngeal cancers with acceptable toxicity. Further
prospective studies with a large number of patients should be
performed with tomotherapy to assess the impact of this new
technique on patient quality of life because of the unique ability of
Tomotherapy to decrease radiation dose to the normal tissues.
Conclusions
Tomotherapy-based IGRT provides excellent loco-regional
control and in patients with locally advanced oropharyngeal
carcinoma with acceptable long-term toxicity. However, acute
toxicity, mainly mucositis remains significant and should be taken
into consideration in future prospective trials.
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